Proactive Investors - Run By Investors For Investors

AusCann Group Holdings welcomes medical cannabis legislation

AusCann is trading up 115% to $0.43 from its February 2017 ASX debut at $0.20.
Australian parliament house of representatives
The bill has now been introduced to the House of Representatives for debate

AusCann Group Holdings (ASX:AC8) welcomes the passing of the Medicinal Cannabis Legislation Amendment (Securing Patient Access) Bill 2017 in the Senate yesterday.

The bill was introduced to expand upon the ability of terminally ill patients to access cannabinoid medicines.

Currently, certain terminally ill patients can only access cannabinoid medicines that are imported on a patient by patient basis.

This bill will enable these terminally ill patients to access cannabinoid medicines that are produced by AusCann in Australia as well as those medicines being imported by AusCann.

Through its strategic partnership with Canopy Growth Corporation, AusCann is able to import cannabinoid medicines that are already being used to treat patients in Canada.

Elaine Darby, managing director, commented

“We welcome the introduction of any measures that further enhances the ability of terminally ill patients to access medications their doctors believe can assist them.

“We look forward to being able to supply these Australian patients with high quality, cost-effective, clinically validated medications that have been produced in Australia.”

Next steps for the bill

The bill has now progressed and has been introduced to the House of Representatives for debate.

AusCann is closely monitoring the progress of this bill and looks forward to the pending legislative change being implemented.

In the interim, AusCann’s medical liaison managers are actively working with Australian doctors that are able to prescribe AusCann’s cannabinoid medicines under current legislation.

WATCH NOW: AusCann Group Holdings positioned to be a leading supplier of Australian cannabinoid

READ NOW: AusCann Group Holdings Ltd granted Australian medicinal cannabis manufacturing licence

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full AC8 profile View Profile

AusCann Group Holdings Ltd Timeline

Related Articles

cannabis tablet
March 01 2019
The company fills a niche in the medicinal cannabis market, as it continues to push forward its suite of precision oral dose products
cannabis extract
January 17 2019
The Kelowna, BC-based cannabis company specializes in the research, development, production, and testing of high-quality cannabis extracts and oils
1540909388_Marijuana-stethoscope.jpg
October 31 2018
The firm wants to become the first publicly listed, globally focused, pure cannabis company

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use